title: Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw.
abstract: Over recent years, several reports have been published on unusual cases of osteonecrosis of the jaw (ONJ) in adults using second- and third-generation nitrogen-containing bisphosphonates such as pamidronate, alendronate, risedronate and zoledronate, but no case has ever been reported either in children or in adult patients taking neridronate. Children and adolescents affected by osteogenesis imperfecta (OI) could belong to a high-risk group for ONJ because bone fragility in OI is associated with a connective tissue malfunction. The purpose of this study is to evaluate the incidence of ONJ in a pediatric population treated with neridronate for OI. A total of 102 pediatric patients with OI who received neridronate infusions for a mean of 6.81 years (SD ± 3.06 years) were clinically assessed for possible ONJ. Eligibility criteria for participation included patients between 1.2 and 24 years old who received cyclical neridronate infusions for at least 1 year. All the patients were reviewed to determine duration, dosage and cumulative dose of their bisphosphonate therapy and were examined clinically to assess their oral health status. We have not demonstrated any occurrence of ONJ in our patients. In conclusion, at the moment insufficient data are available to prove a greater risk of ONJ in children with OI than in children affected by other forms of bone fragility. However, cases may emerge in future because the risk of ONJ seems to be related to the cumulative dose and the duration of therapy.
authors: Department of Life Sciences and Reproduction Sciences, Pediatric Clinic, University of Verona, General Hospital Giambattista Rossi, Piazzale Ludovico Antonio Scuro 10, 37134 Verona, Italy. evelina.maines@gmail.com
authors: Evelina
authors: E
authors: Maines
authors: Elena
authors: E
authors: Monti
authors: Francesco
authors: F
authors: Doro
authors: Grazia
authors: G
authors: Morandi
authors: Paolo
authors: P
authors: Cavarzere
authors: Franco
authors: F
authors: Antoniazzi
mesh_terms: D000293:Adolescent; D000328:Adult; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000453:epidemiology* / Q000209:etiology; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D007558:Italy / Q000453:epidemiology; D008297:Male; D010013:Osteogenesis Imperfecta / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D012306:Risk; D012720:Severity of Illness Index; D013997:Time Factors; D055815:Young Adult
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; C053389:6-amino-1-hydroxyhexane-1,1-diphosphonate